当前位置: 首页 >> 检索结果
2421. [Treatment of hepatic metastases].
Liver metastases usually result in death within 6 months, and excision is the only means of ensuring prolonged survival. Excision is justified in metastases, even multiple, localized in one lobe and arising from cancers of the colon or rectum, provided the cancer has apparently been adequately treated. Excision of metastases of other origins is disappointing. Among palliative treatments, infusion of antimitotic agents into the hepatic artery seems to give better results than dearterialization; implantable micropumps facilitate the infusion and prolong its duration. Embolization and radiotherapy mostly have an analgesic effect. Intravenous chemotherapy is much less effective.
2422. [Recommendations for safe handling of parenteral antineoplastic drugs].2423. [Mode of action and spectrum of activity of cytolytic drugs in clinical oncology].2424. [Clonogenic cultures of human tumors. Potentials and difficulties].
作者: M Rozencweig.;C Sanders.;W Rombaut.;Y Kenis.;J Klastersky.;G Decoster.
来源: Rev Med Liege. 1984年39卷3期134-7页 2425. [Side effects of chemotherapy, their prevention and their treatment].2426. [Value of monoclonal antibodies in the diagnosis and treatment of cancer].2427. [Locoregional and systemic chemotherapy in the treatment of secondary cancers of the liver].2428. [Renal toxicity of 9-hydroxy-2-methylellipticinium].
作者: J P Ryckelynck.;J F Heron.;P Juret.;E De Ranieri.;P Herlin.;A Hardouin.;J Y Le Talaer.
来源: Presse Med. 1984年13卷2期104页 2429. [Post-anesthetic hepatitis. The role of halothane and antimitotic combinations].
作者: R Gounot.;H Perret-Poulat.;H Métafiot.;G Pouyau.;F Freycon.;M Cottier.;M Ollagnier.
来源: Ann Fr Anesth Reanim. 1984年3卷3期212-5页
A 12 year old boy with Burkitt's lymphoma developed severe hepatitis with hepatomegaly, subclinical jaundice, and a small rise in body temperature, associated with an important rise in SGPT and fall in prothrombin titres, 6 days after anticancer chemotherapy and 24 hours after halothane anaesthesia. Hepatitis A and B serology remained negative. This hepatic failure explained perhaps the unusually severe vincristine toxicity which gave rise to a polyneuritis with important sequelae. The association of halothane hepatitis with antimitotic drugs appeared particularly dangerous, and halothane should probably be avoided in all patients been given or about to be given anticancer chemotherapy.
2430. [The risk of infection in leukemic children: a retrospective study of 294 cases].2431. [Industrial hygiene in hospitals].
This paper emphasizes the importance of occupational hygiene in the hospital. By taking into account the differences between hospital hygiene and industrial hygiene one realizes that these sciences are quite complementary. A few occupational stresses or hazards are described some of them being unspecific to the hospital and the other ones being specific i.e. they are not usually present in other industrial situations. Among these are anesthetic gases, ethylene oxide and cytostatic agents. Examples of results obtained during field surveys are given and briefly commented. The occupational hygienist is an important member of the team aiming at the protection of the workers' health in the hospital.
2432. [Specific medicinal treatment of bladder cancers].
作者: M Schneider.;A Thyss.;C Caldani.;G Lesbats.
来源: Bull Soc Sci Med Grand Duche Luxemb. 1984年121卷1期27-35页 2433. [Choriogonadotrophic hormone and placental tumors].
The radioimmunological dosage of choriogonadotrophic hormone is the actual basis for the choice of patients to be treated, to recognize the poor prognosis cases, to adjust the treatment in drugs, doses and durations, to detect the relapses. The clinicien must obey the biologist who is always right.
2434. [Comparative double-blind study: alizapride-metoclopramide].
The anti-emetic action of alizapride was compared to that of metoclopramide in a strict double-blind study of 57 cases files derived from 21 patients treated with anti-mitotic chemotherapy. For each treatment, each patient received two ampoules before and after the chemotherapy. Each ampoule contained either 50 mg of alizapride or 10 mg of metoclopramide. There were 24 good or excellent results and 4 nil results with alizapride and 16 good or excellent results and 13 nil results with metoclopramide. The superiority of alizapride over metoclopramide was therefore established with statistical significance (0.05 greater than p greater than 0.02).
2437. [Adjuvant chemotherapy of cancer of the ovary].
The aim of adjuvant chemotherapy is to cure micrometastatic disease and to prevent relapses after apparently complete surgical exeresis. It is almost always administered after initial surgical treatment, except for stage IA1 malignant epithelial tumours and stage I-II pur dysgerminomas. Chemotherapy combines anthracycline, an alkylating agent, a plant alkaloid and cis-platinum, for 4-8 months. After second-look laparotomy, if no more macro or microscopic tumor have been discovered, adjuvant chemotherapy does not seem necessary. However it is when all residual tumor has been excised or cyto- and/or histologic controls are positive. Optimal schedules are not yet perfectly defined. In some cases, a third look laparotomy should confirm the absence of tumor in order to stop treatment. Side effects (hematologic, gastrointestinal, neurologic, renal) are frequent. It is necessary to recognize patients able to benefit from chemotherapy and to define the least toxic treatment.
2438. [Adjuvant chemotherapy of cancer: immediate costs and long-term risks].
Medical, psychologic, socio-professional and economic side effects of adjuvant chemotherapy are frequent. Some of these are not easily recognized with accuracy. They influence directly the life of treated patients and perhaps later their medical future. They involve the quality of life for cancer patients, after initial curative treatments. Indications for adjuvant chemotherapy cannot be extended without comparative evaluation of their advantages and disadvantages. It is necessary to select patients with the highest probability of improvement in the duration and the quality of life and to give them so active but the least toxic treatments possible.
2439. [Rationalization of adjuvant chemotherapy by induction chemotherapy].
An induction chemotherapy, before any local treatment, allows to precise the chemosensitivity of the primary tumor. These data may help to improve indication and type of a further adjuvant chemotherapy. However there are many biological differences between different sites of the same tumor and along the time, without or after treatment. It is thus impossible to be sure that a chemotherapeutic regimen effective as first treatment on the primary will be equally active on micro-metastases some months later. Many questions in this field will be answered only by controlled studies and careful observations.
2440. [Renal toxicity of 9-hydroxy-2-methyl-ellipticinium].
作者: J P Ryckelynck.;J F Heron.;P Juret.;P Schneider.;P Herlin.;E De Ranieri.;A Hardouin.;J Peny.;J Y Le Talaer.
来源: Nephrologie. 1984年5卷2期59-63页
9-hydroxy-2-methyl-ellipticinium (HME) is an intercaling agent mainly potent in metastatic breast cancer. Its almost complete lack of bone marrow toxicity is of greatest value. However, among 385 patients 20 cases of renal failure were observed: renal failure is gradual, non reversible except in four cases with acute renal failure. Histological and ultrastructural studies, performed in 8 cases, showed exclusively proximal tubular lesions, without glomerular or interstitial lesions. We have evidence that there is a relation between the cumulative dose and the severity of the lesions. A prospective study was done in 30 patients. An increase in enzymuria, proteinuria and glycosuria was observed in most patients after HME infusion. HME is an efficient drug in the treatment of bone metastases of breast cancer. Renal function should be carefully monitored during HME administration.
|